Your browser doesn't support javascript.
loading
Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer.
Lenos, Kristiaan J; Miedema, Daniël M; Lodestijn, Sophie C; Nijman, Lisanne E; van den Bosch, Tom; Romero Ros, Xavier; Lourenço, Filipe C; Lecca, Maria C; van der Heijden, Maartje; van Neerven, Sanne M; van Oort, Anita; Leveille, Nicolas; Adam, Ronja S; de Sousa E Melo, Felipe; Otten, Joy; Veerman, Patrick; Hypolite, Guillaume; Koens, Lianne; Lyons, Scott K; Stassi, Giorgio; Winton, Douglas J; Medema, Jan Paul; Morrissey, Edward; Bijlsma, Maarten F; Vermeulen, Louis.
Afiliación
  • Lenos KJ; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • Miedema DM; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • Lodestijn SC; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • Nijman LE; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • van den Bosch T; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • Romero Ros X; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • Lourenço FC; Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Lecca MC; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • van der Heijden M; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • van Neerven SM; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • van Oort A; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • Leveille N; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • Adam RS; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • de Sousa E Melo F; Department of Discovery Oncology, Genentech, South San Francisco, CA, USA.
  • Otten J; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • Veerman P; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • Hypolite G; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • Koens L; Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands.
  • Lyons SK; Preclinical Imaging, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
  • Stassi G; Cellular & Molecular Pathophysiology Laboratory, Department of Surgical & Oncological Sciences, University of Palermo, Palermo, Italy.
  • Winton DJ; Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Medema JP; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • Morrissey E; MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK.
  • Bijlsma MF; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands.
  • Vermeulen L; Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam, The Netherlands. l.vermeulen@amc.uva.nl.
Nat Cell Biol ; 20(10): 1193-1202, 2018 10.
Article en En | MEDLINE | ID: mdl-30177776
ABSTRACT
Solid malignancies have been speculated to depend on cancer stem cells (CSCs) for expansion and relapse after therapy. Here we report on quantitative analyses of lineage tracing data from primary colon cancer xenograft tissue to assess CSC functionality in a human solid malignancy. The temporally obtained clone size distribution data support a model in which stem cell function in established cancers is not intrinsically, but is entirely spatiotemporally orchestrated. Functional stem cells that drive tumour expansion predominantly reside at the tumour edge, close to cancer-associated fibroblasts. Hence, stem cell properties change in time depending on the cell location. Furthermore, although chemotherapy enriches for cells with a CSC phenotype, in this context functional stem cell properties are also fully defined by the microenvironment. To conclude, we identified osteopontin as a key cancer-associated fibroblast-produced factor that drives in situ clonogenicity in colon cancer.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Madre Neoplásicas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias del Colon / Ensayos Antitumor por Modelo de Xenoinjerto / Proliferación Celular / Microambiente Tumoral Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Cell Biol Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Madre Neoplásicas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias del Colon / Ensayos Antitumor por Modelo de Xenoinjerto / Proliferación Celular / Microambiente Tumoral Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Cell Biol Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos
...